Wednesday, 26 August 2026European Markets

ASETEK Stock Went Down By Over 27% In The Last 21 Sessions

Loading stream...

(VIANEWS) - Shares of ASETEK (Oslo Børs Benchmark Index_GI: ASTK.OL) dropped by a staggering 27.67% in 21 sessions from kr5.53 to kr4.00 at 14:27 EST on Thursday, after two sequential sessions in a row of gains. Oslo Børs Benchmark Index_GI is falling 0.46% to kr1,197.94, after two sequential sessions in a row of losses.

About ASETEK

Asetek A/S, together with its subsidiaries, engages in the designing, developing, and marketing of liquid cooling solutions in Asia, Europe, and the Americas. The company operates through Liquid cooling, Data center and SimSports segments. Its products are used in personal computers, servers, and data centers to provide improved performance, acoustics, and energy efficiency. It serves original equipment manufacturers, resellers, and channel partners. The company was founded in 1997 and is headquartered in Aalborg, Denmark.

Earnings Per Share

As for profitability, ASETEK has a trailing twelve months EPS of kr-0.55.

Volatility

ASETEK's last week, last month's, and last quarter's current intraday variation average was 1.87%, 0.06%, and 9.27%.

ASETEK's highest amplitude of average volatility was 6.80% (last week), 16.77% (last month), and 9.27% (last quarter).

More news about ASETEK (ASTK.OL).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Leadership Exodus Rattles Investor Confidence Amid Capex Boom
High-profile departures at top AI labs — Brad Lightcap's exit from OpenAI and an unnamed researcher's departure from Alphabet/Google that triggered a share-price drop — are surfacing talent retention as a market risk factor even as hyperscalers pour record capital into AI infrastructure. The reaction shows investors treating key-person risk at frontier AI labs as material to valuation, a new fragility layered onto an otherwise bullish AI-driven capex cycle.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Broadcom Inc.
Both facts report EPS for Broadcom Inc. for the same fiscal period (Q1 2026) observed on the same date (2026-02-01). However, they report conflicting values: 1.5 USD per share vs 2.05 USD per share. This is a 37% difference for the identical metric and time period, not a value change over time.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,978
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,978 facts checked against source5,251 source documents archived
Query this data → isubstrate.com